The neuropeptide, neurotensin (NT), appears to play an important role in regulating dopamine (DA) pathways; thus, NT antagonizes DA effects when administered into the nucleus accumbens and striatum and consequently attenuates the motor responses (i.e., locomotion and rearing) to low doses of stimulants of abuse, like methamphetamine (METH). In a reciprocal manner, increases in DA release (such as that induced by METH) profoundly alter NT activity associated with accumbens and striatal DA terminals, causing opposite changes in NT concentration when DA D-l or D-2 receptors are stimulated. These findings suggest a complex interaction between NT and DA systems; because of that interaction NT may have an important influence on responses to CNS stimulants, such as METH. Thus, the principal objective of this proposal is to identify the effects of endogenous NT systems on the changes in DA activity and motor behavior caused by various METH treatments and to elucidate the mechanisms of these effects. The objectives of this proposal will be achieved by determining the consequences of antagonizing endogenous NT activity, with either a selective antiserum raised against NT or a nonpeptide NT antagonist (SR 48692), on the effects of METH. Surprising initial data suggest that NT systems are activated and antagonize DA and motor responses to low (0.5 mg/kg), but, are shut down and have no effect in the presence of high (5 mg/kg) doses of METH. These findings will be extended and the involved DA systems identified. Other findings suggest that NT involvement in the response to low METH doses relates to increased activity caused by DA D-2 receptors. In contrast, NT systems in the response to high doses of METH are shut down by DA D-l and N-methyl-D- aspartate (NMDA; a glutamate subtype) receptors. These hypotheses will be tested. The effects of METH or selective Dl and D2 agonists and antagonists, will be determined by measuring DA and/or NT release with microdialysis probes or push-pull cannulae implanted into the nucleus accumbens, neostriatum or ventricles. The motor response to METH will be evaluated by a Digiscan """"""""Micro"""""""" Analyzer combined with a trained observer blind to the treatment. A better understanding of how METH affects limbic and extrapyramidal NT systems and how they in turn contribute to the response caused by this stimulant may lead to the development of novel therapies for the acute and chronic problems of METH abuse. In addition, these studies will help elucidate the mechanisms whereby important midbrain dopaminergic pathways are regulated and possibly suggest new approaches for treating related psychiatric and motor disorders.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
5R01DA009407-03
Application #
2391027
Study Section
Drug Abuse Biomedical Research Review Committee (DABR)
Program Officer
Frankenheim, Jerry
Project Start
1995-04-01
Project End
1998-03-31
Budget Start
1997-04-01
Budget End
1998-03-31
Support Year
3
Fiscal Year
1997
Total Cost
Indirect Cost
Name
University of Utah
Department
Pharmacology
Type
Schools of Pharmacy
DUNS #
City
Salt Lake City
State
UT
Country
United States
Zip Code
84112
McFadden, Lisa M; Stout, Kristen A; Vieira-Brock, Paula L et al. (2012) Methamphetamine self-administration acutely decreases monoaminergic transporter function. Synapse 66:240-5
McFadden, Lisa M; Hadlock, Greg C; Allen, Scott C et al. (2012) Methamphetamine self-administration causes persistent striatal dopaminergic alterations and mitigates the deficits caused by a subsequent methamphetamine exposure. J Pharmacol Exp Ther 340:295-303
Hadlock, Gregory C; Nelson, Chad C; Baucum 2nd, Anthony J et al. (2011) Ex vivo identification of protein-protein interactions involving the dopamine transporter. J Neurosci Methods 196:303-7
Alburges, Mario E; Hoonakker, Amanda J; Horner, Kristen A et al. (2011) Methylphenidate alters basal ganglia neurotensin systems through dopaminergic mechanisms: a comparison with cocaine treatment. J Neurochem 117:470-8
Alburges, Mario E; Frankel, Paul S; Hoonakker, Amanda J et al. (2009) Responses of limbic and extrapyramidal substance P systems to nicotine treatment. Psychopharmacology (Berl) 201:517-27
Frankel, Paul S; Hoonakker, Amanda J; Hanson, Glen R (2008) Differential response of neurotensin to methamphetamine self-administration. Ann N Y Acad Sci 1139:112-7
Frankel, Paul S; Alburges, Mario E; Bush, Lloyd et al. (2008) Striatal and ventral pallidum dynorphin concentrations are markedly increased in human chronic cocaine users. Neuropharmacology 55:41-6
Alburges, Mario E; Hoonakker, Amanda J; Hanson, Glen R (2007) Nicotinic and dopamine D2 receptors mediate nicotine-induced changes in ventral tegmental area neurotensin system. Eur J Pharmacol 573:124-32
Frankel, Paul S; Hoonakker, Amanda J; Danaceau, Jonathan P et al. (2007) Mechanism of an exaggerated locomotor response to a low-dose challenge of methamphetamine. Pharmacol Biochem Behav 86:511-5
Frankel, Paul S; Alburges, Mario E; Bush, Lloyd et al. (2007) Brain levels of neuropeptides in human chronic methamphetamine users. Neuropharmacology 53:447-54

Showing the most recent 10 out of 32 publications